Anti-VEGF Well Tolerated For Treating Neovascular AMD In Year 3 Of VISION Trial

Monday, December 8, 2008

Ocular Surgery News

Pegaptanib sodium was well tolerated in the third year of testing in patients with neovascular age-related macular degeneration.

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

AdGlare Leaderboard